Home › Prostate Cancer › NCT05926102

The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)

The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS): A Pragmatic Trial of Precision Prostate Cancer Screening

Who can join

Ages 55 to 69 · Men · Healthy volunteers welcome

Inclusion Criteria:

* baseline age 55-69 years
* receipt of regular VA care
* Veteran status

Exclusion Criteria:

* personal history of prostate cancer
* prior prostate biopsy, prostatectomy, or prostate MRI
* known carrier status of rare variant associated with cancer syndrome

About the study

Prostate cancer is the most common non-skin cancer among Veterans and the second leading cause of male cancer death. Current methods of screening men for prostate cancer are inaccurate and cannot identify which men do not have prostate cancer or have low-grade cases that will not cause harm and which men have significant prostate cancer needing treatment. False-positive screening tests can result in unnecessary prostate biopsies for men who do not need them. However, new genetic testing might help identify which men are at highest risk for prostate cancer. This study will examine whether a genetic test helps identify men at risk for significant prostate cancer while helping men who are at low risk for prostate cancer avoid unnecessary biopsies. If this genetic test proves beneficial, it will improve the way that healthcare providers screen male Veterans for prostate cancer.

What is being tested

• Precision screening intervention (genetic)
• Usual care (other)

Sponsor: VA Office of Research and Development · Participants: 5,000 · Started: Feb 1, 2024

Contact the study team

• Charles A Brunette, PhD · Phone: (857) 364-6324

Official record on ClinicalTrials.gov — NCT05926102

Locations in the U.S.

Conditions

• Prostate Cancer
• Genetic Risk Score

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.